Humira "Dear Doctor" Letter Emphasizes Class Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott's letter reinforces the class warning concerning combination use of Amgen's Kineret and another TNF-inhibitor, the company says. Revised labeling for Humira also includes new warnings regarding hypersensitivity reactions and hematologic events.
You may also be interested in...
J&J's Remicade Adds Malignancy Warning To Labeling
New language on lymphoma in the Warnings and Adverse Reactions sections of labeling is substantially similar to that of other TNF-inhibitors – Amgen's Enbrel and Abbott's Humira. J&J is issuing a "Dear Doctor" letter to inform physicians of the changes.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles